Literature DB >> 6683104

Metabolic disposition of prostaglandin E1 in man.

B Rosenkranz, C Fischer, J M Boeynaems, J C Frölich.   

Abstract

Metabolism of [17, 18-3H]prostaglandin E1 was investigated in three healthy male volunteers during intravenous infusion. The infusion rate was 5.0 ng/kg per min. Blood samples were obtained before the end of the infusion as well as 5, 10, 20, 40, 90 and 180 min afterwards; urine and feces were collected until 96 and 72 h, respectively, after the experiment. All samples were analyzed for radioactivity. Urine was further chromatographed, including by high-pressure liquid chromatography, and subsequently analyzed by gas chromatography-mass spectrometry. Radioactivity in plasma rapidly declined during the first 10 min after termination of the infusion, and then was eliminated exponentially with a mean half-life of 181 min, probably reflecting slow excretion of one or more metabolite. 12% of the administered radioactivity could be recovered from feces and 88% from urine. From the radioactive material obtained from urine the following metabolites could be identified (each number represents data of one volunteer): 7 alpha-hydroxy-5,11-diketotetranor-prostane-1,16-dioic acid (10.4, 20.4 and 30.1%), 7 alpha-hydroxy-5,11-diketotetranor-prostanoic acid (8.2, 6.9 and 9.3%), 5 alpha, 7 alpha-dihydroxy-11-ketotetranor-prostane-1,16-dioic acid and its delta-lactone (together accounting for 4.1, 2.1 and 3.8%).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6683104     DOI: 10.1016/0005-2760(83)90023-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.

Authors:  A Leonhardt; H Schweer; D Wolf; H W Seyberth
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 2.  Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation.

Authors:  Kevin Watt; Jennifer S Li; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  J Cardiovasc Pharmacol       Date:  2011-08       Impact factor: 3.105

3.  Effects of salicylic and acetylsalicylic acid alone and in combination on platelet aggregation and prostanoid synthesis in man.

Authors:  B Rosenkranz; C Fischer; C O Meese; J C Frölich
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

Review 4.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

Review 5.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

6.  Moderate changes in linoleate intake do not influence the systemic production of E prostaglandins.

Authors:  A Ferretti; J T Judd; M W Marshall; V P Flanagan; J M Roman; E J Matusik
Journal:  Lipids       Date:  1985-05       Impact factor: 1.880

7.  Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.

Authors:  W Cawello; H Schweer; R Müller; R Bonn; H W Seyberth
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.